Noun
denosumab (uncountable)
(pharmacology) A drug (trademark Prolia and Xgera) that is a genetically engineered monoclonal antibody that reduces bone resorption and increases bone mass by inhibiting osteoclast formation and function and that is administered by injection to prevent fractures associated with osteoporosis and malignant tumors of bone and to treat hypercalcemia associated with various cancers.
Discontinuation of Denosumab (Dmab) is associated with a severe rebound effect on BTMs and BMD for near 24 months. Source: Internet
Denosumab is also effective for preventing osteoporotic fractures. Source: Internet
Not to Diss Denosumab, but More Data Needed in Breast CancerIs it time to jump on the bisphosphonate bandwagon? Source: Internet